about
Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cellsConsumption of flavanol-rich cocoa acutely increases microcirculation in human skin.Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatmentIFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansLiver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain.Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study.Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals.Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.HAART and the liver: friend or foe?Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection.Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.Association of low-density lipoprotein receptor genotypes with hepatitis C viral load.Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves.Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin.Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography.A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection.Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.Impact of observer experience on the reproducibility of transient elastometry in HIV/HCV co-infected patients.Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype.Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
P50
Q28283253-68F23C96-271E-41AB-8F4D-8C1D7FA4590CQ33266345-096D1B7B-6155-45E6-9AB8-FD829A2C07E1Q33422417-1E878964-96C3-40A4-9DBB-8F6642B434B5Q33423922-7DD7A331-C363-4CF5-81C4-BF75FA91EB26Q35036061-9EC48AA9-C6D8-4683-96F4-038948383E85Q35153222-C3A19FEE-AAD8-47F0-851D-D3E9F95953E8Q35915593-2099440B-AABF-42FF-AC94-22DEDBFABBA1Q36167452-0F437183-95E9-4F22-B476-9DFEE3DA5C6EQ38236179-5D555822-6C94-4B3E-89DD-CE2863BBBED4Q38733664-CAC9B292-8E24-4828-BE9B-5652ACBDF98CQ39299968-5082C25F-A7C5-40C3-95DF-A76BE4CDF41CQ39877513-7A1CA410-1097-4C56-B26A-5E2E0B58ABB5Q41008656-7A3538BC-E5F3-4681-B916-1DF3AFBED5E5Q41089110-79AF5D25-07A7-4B3B-B940-91FE096DC0B3Q41117767-D7EC6861-ADA4-4389-9F3D-28502912CDCCQ41620769-9CB84F62-2492-431F-AFE9-AA61DC13DA56Q41991102-FEC01A30-DE7A-4E75-9229-A705D647BE3FQ42197581-EF5A0A10-D87E-413D-8EC4-D92EBB70DF8DQ42239526-EBD4B641-C56E-45A7-A378-FB215E1A221BQ42242404-F8AAEC2D-D8B9-41F2-AA34-7F788B5199A8Q42248749-A136B770-6641-40C1-A0D3-9ECED72B8CB5Q42254820-583606B5-B758-43C1-811C-2DC0FD50EB7BQ42255661-F568515F-A5A2-4B65-B893-553FF1CE9A4CQ42255967-F511525B-3F5E-49DE-89AE-119E2BC03086Q42261289-0B251D48-DD6A-42F5-891F-BBE5441D7F6EQ42262070-BF127167-51FB-4A64-BC7F-6AFA4DC40F61Q42267237-8DD7926D-BB1B-422B-85C2-C49AA673C9A9Q42268590-02C4C4D0-F3B4-4649-B8E5-E02F6C5EEC16Q42272617-857C1337-EFBF-46A7-898E-62957229F20CQ42282496-40D1DF5C-160D-4C74-8AC8-A8A95505F2BCQ42922285-AE0449C3-95B5-4DE8-B014-AD22C1611EB9Q42959234-F135B774-4804-43C8-9497-7C3677BE2A6DQ42977958-1048D834-DA46-4235-AE22-FD4340F42B8FQ42978101-291C63C6-F8D8-4F4F-84AE-09D66D31BC2FQ42981865-9FFB6C75-3045-48D8-9788-34743C7F880FQ42985117-1D603C3E-C7B7-4436-A86F-059C520B073EQ42990615-8EEE138A-1062-44E7-9269-A253B6DAC4D9Q43000776-84F23E77-9A5A-4BF9-A52C-D89C34FBBB49Q43034902-24FE47FF-B1A8-4892-ACDA-55D9BFFDAB81Q43040351-2BD240E8-E5EE-415F-AA35-FB57643C6703
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Karin Neukam
@ast
Karin Neukam
@en
Karin Neukam
@es
Karin Neukam
@sl
type
label
Karin Neukam
@ast
Karin Neukam
@en
Karin Neukam
@es
Karin Neukam
@sl
prefLabel
Karin Neukam
@ast
Karin Neukam
@en
Karin Neukam
@es
Karin Neukam
@sl
P214
P106
P1153
13609387100
P21
P214
P31
P496
0000-0003-3875-1013
P735
P7859
viaf-18330081